Living on this planet for over three decades, I've come to a rather blunt realization: money can buy almost anything. It has an uncanny ability to turn the impossible into the possible. Whenever a business proposal gets rejected or a door slams shut, my first instinct is almost always, "Did I just not offer enough money?"
But what if money could buy the ultimate unfair advantage? What if you could literally purchase your future child's IQ, select their height, and guarantee they won't struggle with their weight?
It sounds like the plot of a dystopian sci-fi novel. But it is already unfolding right now. Thanks to exponential advancements in genetic engineering, Silicon Valley startups are turning this into our reality. We are no longer just talking about IVF miracles or finding clues to cure rare diseases. We are talking about actively manipulating human DNA and selecting intelligence at the embryonic stage.
Selecting Your Child Like a Video Game Character
Enter companies like Nucleus Genomics and Herasight. They offer predictive analysis based on the genetic data of embryos during the IVF process. And yes, that data explicitly includes predicted IQ scores.
Nucleus charges $5,999 for this peek into the future. Herasight's premium services can cost up to $50,000. When you log into the Nucleus platform to review your embryo analysis, it feels unnervingly like customizing a video game character. Their marketing doesn't even try to hide the ambition.
The Silicon Valley Elite's Obsession With DNA
This designer baby menu is heavily targeting one specific demographic: the Silicon Valley elite. These are tech billionaires who genuinely believe their wealth is a direct result of superior genetics, and who feel a duty to pass that intelligence down to save humanity.
Elon Musk is the loudest voice in the room.
"There are not enough people. One of the biggest risks to civilization is the low birth rate and the rapidly declining birthrate. If people don't have more children, civilization is going to crumble."
 |
| Spreading his 'superior' genes to save the future |
Musk publicly argues that Earth needs more high-IQ individuals to safeguard civilization. He is putting his DNA where his mouth is, reportedly fathering at least 14 children. He even micromanages the birthing process itself. According to his partner Claire, the mother of his 13th child, Musk demanded a C-section rather than a natural birth. His reasoning was that a C-section would allow for a larger head, meaning a bigger brain and higher intelligence.
Musk is also known to utilize embryo genomic analysis. Look at the cap table of ORCHID, another embryo screening startup. It reads like a Silicon Valley who's who: Dylan Field, founder of Figma; Brian Armstrong, founder of Coinbase; and Anne Wojcicki, founder of 23andMe. Sam Altman invested in Genomic Prediction, a direct competitor in the space. And Nucleus is heavily backed by Peter Thiel.
Modern-Day Snake Oil or Exponential Growth?
Not everyone is applauding. Many experts heavily criticize predicting IQ from genetic data, citing severe limitations and low reliability. One American statistical geneticist dismissed the practice outright, calling genomic IQ prediction "modern-day snake oil" and a borderline scam.
But the genetic engineering market is already deeply embedded in daily life, from ancestry DNA kits to disease prediction tests. Even the recent explosion of IVF is a direct byproduct of genetic engineering.
The numbers tell the story. The world's first IVF baby was born in the UK in 1978. Based on data from the University of New South Wales, up to 13 million IVF babies were born worldwide between 1978 and 2018. Entering the 21st century, that growth curve went exponential. Researchers estimate that since 2019, 3 to 4 million IVF babies have been born annually. By 2024, the cumulative global total could reach a staggering 17 million.
The Ultimate Slippery Slope and the CRISPR Accelerator
The moral dilemma is heavy. How far should humans intervene in the beginning of life? Editing genes for non-therapeutic enhancement is widely condemned as crossing the line. Even for curing diseases, tampering with human embryos demands extreme caution. A tiny, well-intentioned push at the top of this slope can send us rolling into a future we can no longer control.
What pushed us down that slope at breakneck speed was the discovery of CRISPR.
 |
| The duo who turned DNA into a customizable document |
Published in the journal Science in June 2012, the paper revealed that CRISPR, originally a bacterial defense mechanism against viruses, could be weaponized as genetic scissors. You could now cut and paste DNA sequences like editing a Word document. Less than a decade later, the two pioneering scientists behind it, Emmanuelle Charpentier and Jennifer A. Doudna, won the 2020 Nobel Prize in Chemistry.
Older gene-editing tools existed before, but CRISPR's efficiency and precision were on an entirely different level.
Crossing the Line: China's Frankenstein
He Jiankui, dubbed China's Dr. Frankenstein, announced in 2018 that he had created the world's first babies with manipulated DNA. Seeking to solve the pregnancy dilemma of an HIV-positive father and an HIV-negative mother, he edited the embryos' DNA to grant HIV resistance.
The global scientific community was outraged. The Chinese government launched an immediate investigation. He Jiankui was sentenced to three years in prison and fined 3 million yuan. After serving his time, he is already planning to resume his research.
And this ambition isn't isolated to rogue scientists. Back in Silicon Valley, Coinbase CEO Brian Armstrong publicly posted about his interest in embryo gene editing on social media, actively recruiting experts for a new embryo editing team.
The $2.2 Million Cure and the Biological Divide
Despite the rogue actors, many brilliant minds are using CRISPR for its noblest purpose: curing the incurable.
 |
| Healthy red blood cells vs. sickled cells |
Take sickle cell anemia. A chromosomal abnormality causes red blood cells to take a sickle shape instead of a disc, preventing smooth blood flow and causing chronic anemia and liver dysfunction. Researchers deployed CRISPR to fix this broken chromosome and created the world's first CRISPR-based therapeutic drug: Casgevy. Companies like CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics are rushing into this life-saving market.
But there is a massive catch. We are still in the early stages, and the price tags are astronomical. A single treatment of Casgevy costs $2.2 million.
The embryo analysis services we discussed earlier are exclusively for the wealthy, and even standard IVF is overwhelmingly expensive without government subsidies.
"If only the wealthy can afford to optimize their embryos and cure their genetics, we are hurtling toward a future where the gap between the rich and the poor is no longer just financial. It becomes biological."
The Shadow of Extreme Pro-Natalism
This Silicon Valley trend of tech-elite pro-natalism is now intertwining with conservative politics. Politico recently sounded the alarm, warning that some extreme pro-natalist movements could be masking deeply racist agendas. Certain factions argue for increased birth rates specifically to ensure a larger white population and to outnumber progressive voters with conservative offspring. They view genetic engineering as the ultimate tool to accelerate this demographic shift.
Genetic engineering is deeply controversial, yet it has already infiltrated our reality. We hold an incredibly powerful tool that offers hope for conquering incurable diseases. But lurking in its shadow is the seed of a new kind of discrimination.
I wish these concerns were just paranoid overreactions. But Silicon Valley's elite and political power players are already weaponizing this technology faster than anyone else.
Where is the future of genetic engineering, and the future of humanity, heading? Let me know your thoughts in the comments below.
Lagtest Insight: []
Curious about the real stories behind big tech, crypto, and everyday economics? 👉👉👉Subscribe to The Techtonic for your weekly dose of easy-to-read business trends.
댓글 쓰기